Oral sessions summaries
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Dynamic Forehead Lines Following Glabellar Line Injections
Expert commentary by Kimberly Butterwick, MD
AAD VMX 2020 - Oral session
Lebrikizumab, a High-Affinity IL-13 Inhibitor, Demonstrates Rapid and Clinically Meaningful Improvements in Quality of Life Measures in a Phase 2b Trial of Moderate-to-Severe Atopic Dermatitis Patients
Expert commentary by Peter Lio, MD, FAAD
AAD VMX 2020 - Oral session
Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 JADE MONO-2 Study
Expert commentary by Peter Lio, MD, FAAD
AAD VMX 2020 - Oral session
Autoimmune Connective Tissue and Bullous Disease
Expert commentary by Martina Lambertini, MD
AAD VMX 2020 - Oral session
Predicting Cancer Survival Outcomes of Anti-TNF, IL-17, and IL-23 using Gene Expression Data
Expert commentary by Christine J Ko, MD
AAD VMX 2020 - Oral session
What’s New in Dermatopathology: Translational Research
Expert commentary by Christine J Ko, MD
AAD VMX 2020 - Oral session
What’s New in Dermatopathology: Infections
Expert commentary by Jules Lipoff, MD
AAD VMX 2020 - Oral session
Higher BMI is Associated with Increased Toxicity in Patients Undergoing Pembrolizumab Treatment for Advanced Melanoma
Expert commentary by Martina Lambertini, MD
AAD VMX 2020 - Oral session
Pediatric Dermatology: Therapeutic and Diagnostic Pearls
Expert commentary by Antonio Torrelo, MD
AAD VMX 2020 - Oral session
Pediatric Contact Dermatitis
Expert commentary by Swen Malte John, MD, PhD
AAD VMX 2020 - Oral session
Pityriasis Rubra Pilaris Treated with Ixekizumab – An Open-Label Pilot Trial
Expert commentary by Peter Lio, MD, FAAD
AAD VMX 2020 - Oral session
The Effect of Adding Combined Oral Contraceptives or Metformin to Laser Hair Removal Treatment on the Quality of Life of Polycystic Ovarian Patient with Hirsutism: A Randomized Control Trial
Expert commentary by Shady Mahmoud Ibrahim, MD
AAD VMX 2020 - Oral session
Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis (IMMerge): A Phase 3 Trial
Expert commentary by Kirk Barber, MD
AAD VMX 2020 - Oral session
The Longitudinal Evolution of Skin Microbiome of Children from Birth to 10 Years of Age
Expert commentary by Lisa M. Arkin, MD
AAD VMX 2020 - Oral session
Making Teledermatology Work for You: How to Choose the Right Platform for You
Expert commentary by Jules Lipoff, MD
AAD VMX 2020 - Oral session
Update on JAK Inhibition for Vitiligo
Expert commentary by Aunna Pourang, MD
AAD VMX 2020 - Oral session